ERBB2 and neoplasm: Upregulation of HER2 in MutL− patient tumors also independently prognosticates worse disease-specific survival in Cox Proportional Hazards analyses when considering PR status, tumor stage, and TP53 mutational status as confounding variables (Fig. 1C).